Tumor necrosis factor-α and its role as a mediator in myocardial infarction: A brief review  by Tian, Ming et al.
Available online at www.sciencedirect.comScienceDirect
Chronic Diseases and Translational Medicine 1 (2015) 18e26
www.keaipublishing.com/en/journals/cdtm/Review
Tumor necrosis factor-a and its role as a mediator in myocardial
infarction: A brief review
Ming Tian a, Yun-Chuan Yuan a,b, Jia-Yi Li a, Michael R. Gionfriddo c,d,
Rong-Chong Huang a,*
a Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China
b Department of Endocrinology, The Third Gorges Centre Hospital of Chongqing, Chongqing 404100, China
c Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN 55905, USA
d Mayo Graduate School, Mayo Clinic, Rochester, MN 55905, USA
Received 2 November 2014
Available online 22 March 2015
www.cdatm.orgAbstractTumor necrosis factor-a (TNF-a) contributes to myocardial infarction (MI) injury. Polymorphism of TNF-a gene promoter
region and secretion and release of TNF-a and its transformation by a series of signaling pathways are all changed at different points
of pathophysiological process in MI. Researches also investigated TNF-a antagonists and their potential therapeutic role in the
setting of MI and heart failure at both molecular and clinical level. This article briefly reviews TNF-a and its mechanism as a
mediator in MI.
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factors at cell level are involved. Among them, the
inflammatory immune response occurs in infarcted
myocardium and neighboring tissues. This immune
response manifests as an acute necrosis, hypertrophy,
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Although both medication and surgical intervention
can mitigate the clinical symptoms, the infarcted, dead
myocardium remains an issue and could become sub-
strate for chronic diseases. In recent years, the appli-
cation of stem cells with pluripotent differentiation and
proliferation for regenerative treatment of MI has been
investigated. Researchers showed that tumor necrosis
factor-a (TNF-a), as a key regulating factor in the
inflammatory reaction, not only acted in combination
with its ligand as a mediator in the inflammatory im-
mune response but also worked independently in the
setting of myocardial repair. In this article we brieflyElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
19M. Tian et al. / Chronic Diseases and Translational Medicine 1 (2015) 18e26review the TNF-a origin, function, mechanism, gene
polymorphism, and recent development in our under-
standing of this important mediator and its role during
MI and the post MI tissue repair.
Source and biological function of TNF-a
TNF-a has two forms in the body: membrane-
associated TNF-a (mTNF-a) and secreted TNF-a
(sTNF-a) with molecular weights of 26 and 17 kD,
respectively. sTNF-a is generally considered the active
formofmTNF-a; this activation frommTNF-a to sTNF-
a is facilitated by TNF-converting enzyme (TACE).
TNF-a is a ubiquitous cytokine. Many cells have the
ability to produce and release it, including monocyte-
macrophages, lymphocytes, smooth muscle cells, fi-
broblasts, endothelial cells, epithelial cells, and osteo-
blasts. TNF-amRNA is also expressed in the lung, liver,
spleen, thymus, and kidney under the physiological
conditions. Inflammatory factors such as invasion of
bacteria and viruses can rapidly induce the heart,
pancreas, and other organs to synthesize and express
TNF-a.1 Many studies2e4 of the heart have shown that a
variety of injuries and inflammatory states, such as MI,
myocardial ischemia, reperfusion, cardiac bypass sur-
gery, and chronic heart failure (HF), can promote the
production of TNF-a by cardiomyocytes.
Biological activity of TNF-a is realized through the
combination of TNF-a and its receptor, TNF-a re-
ceptor (TNFR), which is expressed in the cell mem-
branes. TNFR is divided into two types, namely
TNFR1 and TNFR2, with molecular weights of 55 and
75 kD, respectively. TNFR1 is expressed across most
of the surface of cell membrane, whereas TNFR2 is
mainly expressed on the surface of endothelial cells
and hematopoietic cells. Remarkably, the expression of
TNFR2 gradually decreases with age.5 Furthermore,
TNF-a and TNFR1 are confirmed to be expressed in
both myocardial infarct zone and non-infarct zone
upon MI, while TNFR2 is only expressed within the
myocardial infarct zone.6 This suggests that the heart is
both a target for and producer of TNF-a.
The activated TNF-a, sTNF-a, can combine with
different receptorsdTNFR1 or TNFR2don the sur-
face of a cell and then activate a variety of enzymes
and regulate protein synthesis, resulting in a wide va-
riety of biological effects. It can regulate the body's
immune function and kill tumor cells directly; partic-
ipate in the body's inflammatory response, tissue injury,
shock, and other pathological process; and is also
closely associated with the pathophysiology of several
autoimmune diseases.7Gene polymorphism of TNF-a and MI
Individual susceptibility plays an important role in
the development of MI. Single nucleotide poly-
morphisms (SNPs) do not directly cause a healthy in-
dividual to develop MI, but may lead to individual
susceptibility to a particular environmental factor or
otherwise make an individual susceptible to MI.
Studies have confirmed that a G/A polymorphism ex-
ists in the 308 promoter region (the 308th bp in the
upstream region of transcription start site) of TNF-a
gene, which may affect the transcription, expression,
and biological activity of TNF-a. However, research on
the relationship between SNPs in this region and the
incidence of MI is contradictory. Recent research8 has
shown that an individual's susceptibility to MI was
closely related to genetic factors, which had trans-
racial and intra-racial differences.
Antonicelli et al9 found that in Italians, people with
the TNF-a-AAþGA polymorphism were at a higher
risk of ST-segment elevation MI than those not
expressing the polymorphism. Chang et al8 found that
there appeared to be gender differences in susceptibility
to acute MI, which was induced by the polymorphism
of TNF-a-308A/G. Males with TNF-a-308AAþGA
were more susceptible toMI compared to males without
the polymorphism. Interestingly, this difference in
susceptibility between those with and without the
polymorphism was not seen among women. Chang et al
considered that this might be related to the 308th bp in
the upstream region of transcription start site of TNF-a,
where an adenine nucleotide replaced a guanine
nucleotide and in doing so, enhanced the translation of
TNF-a mRNA. Consequently, the secretion of TNF-a
into plasma was increased and apoptosis initiated
because of the presence of abnormal activation of
apoptosis pathways of cardiomyocytes, thus acceler-
ating the formation and rupture of unstable plaques,
which further increased the risk of cardiovascular
events. While this explanation is compelling, the spe-
cific molecular mechanism remains to be elucidated.
Chu et al10 conducted a clinical case-control study and
meta-analysis on the Chinese Han population to inves-
tigate the relationship between the polymorphism of
TNF-a-308A/G and susceptibility to MI, which
included a total of 10 items (including gender, age,
smoking, and diabetes) with 1975 enrollees. They found
in both their case-control study and meta-analysis that
there was no association between the TNF-a 308A/G
polymorphism and the risk of MI.
In addition to the -308 polymorphism, several other
polymorphisms exist in the gene for TNF-a, including
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C/T polymorphisms in the -806 and -857 sites. Recent
research suggests that these polymorphisms may be
associated with susceptibility to MI. Through stratified
analysis on gender and region, Bennet et al11 found
that compared to carriers of the TNF-a-238G allele,
females with the TNF-a-238A allele had a lower risk
for MI. Hou12 also had similar findings: based on a
multivariate analysis on polymorphisms of TNF-a in
804 Han Chinese patients with coronary heart disease
(504 with a history of MI) and 905 healthy controls, it
was found that compared with the carriers of the TNF-
a-238G allele, nonsmokers with the TNF-a-238A
allele had a lower risk for coronary heart disease and
lower susceptibility to MI. Thus it could be speculated
that transformation from adenine to guanine at the -238
promoter regions of TNF-a gene might lead to the
reduction of mRNA transcription activity and thus
cause the decrease in generation of TNF-a. Kaluza
et al13 confirmed this hypothesis by using luciferase
reporter assay. They found that transcriptional activity
in people with the TNF-a-238A allele was significantly
reduced, and compared with the control group,
monocytes carrying the TNF-a-238A allele in the pe-
ripheral blood, when stimulated, produced dramati-
cally less TNF-a. It is worth noting that in individuals
who smoke, polymorphism of TNF-a-806-C/T signif-
icantly increased their susceptibility to MI.12 However,
since this polymorphism is rare, the extent that it af-
fects TNF-a expression and function is not yet clear
and needs to be further studied and its role in
increasing susceptibility to MI confirmed. Bennet
et al11 found that in healthy smokers, compared with
individuals carrying the TNF-a-857C allele, in-
dividuals with the TNF-a-857T allele had significantly
increased levels of sTNF-a. Bennet et al believed that
smoking increased the activity of NF-kВ in vivo, thus
inducing the expression of TNF-a and this induction
was greater in individuals carrying the TNF-a-857T/T
allele. Interestingly, despite the increased levels of
TNF-a, these individuals were not more susceptible to
MI. This lack of correlation may be reflective of a
threshold phenomenon, in that a certain level of TNF-a
may be reached before any increased susceptibility to
MI is seen.
It is well known that TNF-a can influence the lipid
metabolism, increase insulin resistance of obese in-
dividuals, and play an important role in the patho-
physiology of MI. The complement cascade can also
promote the progress of atherosclerotic plaques
through participation in the inflammatory reaction of
local blood vessels, and thus may play a leading role inthe regulation of local inflammatory response to MI.
Therefore, is there a potential synergy between poly-
morphisms in the TNF-a gene and the complement
regulatory gene? Szalai et al14 studied 318 patients
with severe coronary heart disease and 248 healthy
controls and found that individuals with alleles TNF-a-
308A or C4A*Q0 had increased susceptibility to MI.
Furthermore, individuals carrying both the TNF-a-
308A and C4A*Q0 alleles were at an even greater risk
of MI. They argued that when both the genes were
expressed, their products interacted, resulting in co-
stimulatory activity which led to an inflammatory re-
action. This reaction disrupts the inflammatory balance
and may lead to the rupture of unstable plaques, thus
facilitating the transformation from stable coronary
heart disease to MI.
Overall, the influence of polymorphisms in TNF-a
on the risk of MI remains controversial. Influences of
different subjects, samples, and other environmental
factors on the results cannot yet be ruled out. Thus,
despite some evidence that polymorphisms in TNF-a
increase susceptibility to MI, more research is needed
to confirm the role of TNF-a and its variants in the
pathogenesis of MI.
TNF-a and its receptors as well as MI and
complications
TNF-a is not expressed in normal cardiomyocytes,
but after MI, myocardial tissue with ischemia and
anoxia activates cardiomyocytes and myocardial local
mononuclear macrophages, which causes the myocar-
dium in the infarcted zone and infarction border zone
to produce large amounts of TNF-a.15 Concurrently,
the expression of TNFR1 and 2 also increases signifi-
cantly,16 with the degree of elevation positively
correlated with the infarction size, the damage to heart
function, and the risk of this disease.17 This suggests
that the expression of TNF-a and its receptors is
closely related to the pathogenesis of MI.
After MI, TNF-a is combined with TNFR1/2 to
play a pleiotropic role: When combined with TNFR1,
the complex is mainly involved in the inflammatory
reaction and ventricular remodeling after MI, leading
to cardiomyocyte apoptosis and cardiotoxicity;
whereas when combined with TNFR2, the complex
inhibits the inflammatory reaction and ventricular
remodeling after MI, thus reducing the apoptosis of
cardiomyocytes and protecting the heart.17 TNF-a thus
has a dual function in myocardium after MI that acts
with time and dose dependence; in the short term, low
doses of TNF-a could protect the myocardium; in the
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toxic effects on cardiomyocytes.18 In addition, TNF-a
can also affect the cardiomyocyte metabolism and
weaken the balance between inflammatory and anti-
inflammatory factors in MI zone.
TNF-a and MI
TNF-a, interacting with TNFRs after MI, has broad
biological activities. When TNF-a combines with
TNFR1, the secretion of apoptosis-related proteins
(e.g., FADD and TRADD) and inflammatory factors
increases, which promotes the progress of ventricular
remodeling.5,19 Arslan et al20 found that TNF-a in
combination with TNFR1 induced the secretion of
apoptosis-related proteins with RIP1 (receptor inter-
acting protein 1) dependence, which could be blocked
by activation of TAK1 (TGF b-activated kinase-1).
They also found that TNF-a combined with TNFR1
could activate the NF-kВ pathway, intensify endothe-
lial cells to express VCAM-1 and ICAM-1, and in-
crease the infiltration of neutrophils into the infarction
area, and even cause delayed generation of toxic sub-
stances such as superoxide and perforin and seriously
influence myocardial contraction and recovery from
MI.21
While NF-kB is activated by the combination of
TNF-a and TNFR2, expression of inflammatory cyto-
kines IL-6 and IL-1b is downregulated to reduce the
injury resulting from the inflammatory reaction.
Additionally, expression of angiogenic growth factors
VEGF and bFGF is increased to accelerate neo-
vascularization, thus improving the prognosis of MI.
Furthermore, downregulated TNFR2 can cause the
enhancement of TNFR1.5,19 Westbrook et al22 found
that the combination of TNF-a and TNFR1/2 could
cause DNA damage in various cells including T lym-
phocytes, but NF-kВ inhibitors and IL-10 could
significantly reduce the DNA damage. Therefore, it
was speculated that the mechanism of DNA damage
might be an imbalance of the redox reaction due to
reactive oxygen species (ROS) produced by the inter-
action of TNF-a and TNFRs. However, whether this
mechanism is actually occurring in cardiomyocytes
during MI is yet to be clarified.
Combination of adiponectin, expressed by adipo-
cytes, and its ligand AdipoR1, which is on the surface
of cardiomyocytes, could increase the intake of
glucose, enhance lipid metabolism, increase sensitivity
of cardiomyocytes to insulin and anti-atherosclerosis;
weaken the inflammatory reaction and apoptosis of
cardiomyocytes and reduce oxidative stress; andmaintain and improve heart function. After MI, how-
ever, the increased TNF-a combined with TNFR1
upregulates the secretion of ATF3 (activating tran-
scription factor 3), an adiponectin expression inhibitor
which reduces the secretion of adiponectin, while
TNF-a combined with TNFR2 downregulates the
expression of ATF3 to increase the secretion of adi-
ponectin. Thus, the overall influence of ATF3 on adi-
ponectin is dependent on the balance between the
combination of TNF-a with TNFR1 and TNFR2.23,24
It is notable that TNF-a can play a protective role
independently of its receptors. Rathi et al25 found that
after MI, low concentrations of TNF-a in vivo inhibited
KCL-induced migration of Ca2þ to cardiomyocytes,
thus improving myocardial systolic function. Lacerda
et al26 had shown that low doses of TNF-a could
inhibit the function of mitochondrial state 3 respiration
after anoxia-reoxygenation injury of cardiomyocytes,
reduce the release of proton leak-dependent uncou-
pling protein and transmembrane potential, weaken the
glutamate-dependent breath, and increase the recovery
of mitochondrial respiratory rate, thus improving
mitochondrial function. This protective mechanism is
realized with the regulation of the ROS as well as the
sphingomyelin pathway. In later studies, Lacerda
et al27 also found that a certain amount of TNF-a
in vivo could also inhibit the secretion of leptin to
reduce the injury caused by myocardial ischemia/
reperfusion in diabetic mice.
TNF-a and myocardial ischemia/reperfusion
injury after MI
During reperfusion therapy after MI, ischemia/
reperfusion injury or no-reflow occurs frequently,
which is closely related with TNF-a and often
accompanied by arrhythmia, myocardial stunning, left
ventricular systolic dysfunction, microvascular injury,
and progressive myocardial necrosis. The pathological
mechanisms include excessive accumulation of Ca2þ
in cardiomyocytes, production of large amounts of oxy
radicals, and activation of a variety of oxidoreduc-
tases.28,29 TNF-a is a key regulator in the process
through several ways,2,30,31 such as combining with
TNFR1 to induce the synthesis of NO, reducing the
sensitivity of myofilament to Ca2þ, or activating
sphingomyelinase to weaken the release of Ca2þ
induced by Ca2þ, thus leading to the occurrence of
arrhythmia and a decrease in ventricular systolic
function. TNF-a can also activate the NF-kB pathway
by TNFR1, which results in the vicious circle of TNF-
a and pro-inflammatory cytokines, which further
Fig. 1. Proposed outline of the pathway of tumor necrosis factor a (TNF-a) synthesis and effect of TNF-a on myocardial contractility. TNF-R:
TNF-a receptor; MAPK: mitogen-activated protein kinase; NF-kB: nuclear factor kappaB; mRNA: messenger RNA; pro-TNF-a: TNF-a pro-
peptide; cGMP: cyclic GMP; iNOS: inducible nitric oxide synthase; NO: nitric oxide.
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TNFR2 to a certain extent. Some of these pathways are
shown in Fig. 1.
TNF-a and arrhythmia after MI
TNF-a plays the central role in inflammatory
response and immunoregulation as the acute phase
reactive proteins in vivo, and MI itself also involves in
the inflammatory reaction. TNF-a also participates in
the ventricular remodeling and repairs process after
MI. Ventricular arrhythmia, however, is considered as
one of the common complications after MI, so does
TNF-a also play a role in it?
Xiao et al32 found that in mice which had experi-
mentally induced MI, the occurrence of ventricular
arrhythmia (including ventricular premature beat, ven-
tricular tachycardia, sinus bradycardia, and arrhythmia)
correlated with an increased level of TNF-a protein and
mRNA within the infarcted area. Moreover, Xiao et al
observed mice hearts in vitro and found that TNF-a
could significantly increase Ca2þ concentration in car-
diomyocytes, which could be blocked by TNF-a in-
hibitors. It is well known that the pathogenesis of
arrhythmia is correlated with an imbalance of ion flow
in cardiomyocytes, and TNF-a is able to regulate this
ion flow. TNF-a can adjust the internal flow of Ca2þ in
cardiomyocytes by the PLA2/AA pathway, thus
affecting the contraction of cardiomyocytes. TNF-a can
also restrain the delayed rectifier potassium current in
the PKA way. Thus, TNF-a can increase the Ca2þ
concentration of cardiomyocytes after MI; until the
delay after depolarization of cardiomyocytes reachedthe threshold, arrhythmia occurred. Results similar to
Xiao et al were seen by Shimoda et al.33
Based on Xiao's experiment, Chen et al15 further
found that at 10 min after MI, the level of TNF-a
protein and mRNA began to rise in the ischemic
infarcted zone and infarction border zone of myocar-
dium in mice. This increase peaked at 20e30 min and
then the level declined gradually. Time for appearance
of ventricular fibrillation is basically identical with
TNF-a concentration curve. During this period,
dispersion of monophasic action potential duration
(MAPD) in infarction border zone increased, but no
such change was found in the infarction border zone
or normal region. TNF-a inhibitors significantly
decreased the frequencies of ventricular fibrillation and
dispersion of MAPD in infarction border zone, sug-
gesting that TNF-a could increase the risk of ventric-
ular fibrillation after MI by increasing the dispersion of
MAPD in infarction border zone.
TNF-a and progress of HF after MI
After MI, there is significant rise in TNF-a in vivo,
which affects the occurrence, development, and prog-
nosis of HF, including promotion of left ventricular
dilation and remodeling, which result in left ventricular
systolic dysfunction and regulation of cardiomyocyte
hypertrophy. For individuals with HF due to MI, the
higher the concentration of TNF-a in vivo, the weaker
their predicted cardiac function, and the higher the
mortality of the individual.34
Researches showed that TNF-a could be involved in
the process of HF through a series of signaling
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adrenergic receptors, increasing the generation of ROS,
and prompting the synthesis of inducible nitric oxide
synthase (iNOS). In addition, TNF-a might also in-
crease the secretion of other pro-inflammatory cyto-
kines (e.g., IL-6, IL-1), which in turn reinforce the
myocardial injury potential of TNF-a. Moreover, TNF-
a could downregulate the synthesis of cardiac a-actin
and a-myosin heavy chain which is related to a decline
in ventricular systolic function in HF.37 In addition to
the decline in ventricular systolic function, for in-
dividuals with HF after MI, continuous high expression
of TNF-a in vivo could also change the structure of the
heart, such as promoting hypertrophy of car-
diomyocytes and increasing the apoptosis of car-
diomyocytes and myocardial fibrosis.
Excessive expression of TNF-a in cardiomyocytes
after MI or infiltration of chronic high doses of TNF-a
in vivo often causes adaptive hypertrophy of car-
diomyocytes,38,39 thus leading to left ventricular hy-
pertrophy and dilation.40 TNF-a could increase the
transcription of hypertrophic genes by activation of
p38MAPK and NF-kB pathways.41 The changes in
protein expression induced by TNF-a are ROS depen-
dent.42 Therefore, although TNF-a antagonists can be
used to balance the excessive expression of TNF-a
in vivo, TNF-a then can effectively weaken the hyper-
trophy and remodeling of cardiomyocytes after HF.43
Some studies have found that in HF the apoptosis of
cardiomyocytes increases significantly40; oxidative
stress enhances and acts on the constituent proteins of
mitochondrial permeability transition pore (MPTP)d
adenosine transitional protein and voltage-dependent
anion channel (VDAC) to open the pore.44 TNF-a
could increase the release of mitochondrial cytochrome
c to the cytoplasm by improving the synthesis and
secretion of arachidonic acid,45 to weaken the mito-
chondrial transmembrane potential and induce
apoptosis of mature ventricular myocytes and even the
incidence of pacing-induced HF.36,46 TNF-a directly
regulates mitochondrial function, especially the
increased formation of ROS which increases the
release of cytochrome c, which initiates apoptotic
signals. In addition, the increasing Ca2þ may stimulate
the apoptosis of cardiomyocytes, which may be related
to the activation of calpain induced by increased TNF-
a.47,48 It is important to note that the combination of
TNF-a and TNFR1 could cause the continuous acti-
vation of NF-kВ and the special position of iNOS in
the mechanism of cardiomyocyte apoptosis cannot be
ignored31; however, the role of TNFR2 in the protec-
tion of myocardial function also should not be ignored.Related studies confirmed that upon HF, synthesis
of interstitial infiltration, extracellular matrix compo-
nents, and connexin was all increased to some extent.40
By increasing the synthesis of ROS and reducing the
secretion of tissue inhibitor of MP (TIMP), TNF-a
upregulated the expression of matrix metalloproteinase
(MMP)49 and broke the balance between MMP and
TIMP, thus changing the content of myocardial
collagen fibers, which eventually aggravated ventricu-
lar remodeling and even caused ventricular rupture.31
In spite of this understanding, basic and clinical
research aiming at treating HF through antagonism of
TNF-a has not been successful. Berthonneche et al50
found that in mice with HF after MI there was no ef-
fect when they were given monomeric recombinant
human soluble TNF-a receptor type II (soluble TNFR2)
treatment. Eugene et al treated HF patients with inflix-
imab (a TNF-a inhibitor), and the results showed that
low doses had no benefit in individuals with HF, while
high doses of infliximab, on the contrary, led to the
deterioration of HF.51 Therefore, although research
suggests a link between TNF-a and the pathogenesis of
HF, the potential exploitation of this pathway for treat-
ment purposes needs further studies.
Stem cell therapy when TNF-a adjusting MI
Stem cells and hematopoietic cells have strong
regeneration and differentiation abilities and can
differentiate into other cells including cardiomyocytes.
Therefore, in recent years, studies on stem cells and
hematopoietic progenitor cells to repair myocardial
injury have become common. In addition, the inflam-
matory reaction is involved in the pathological changes
of almost all cardiovascular diseases (e.g., MI, HF, and
myocarditis); therefore, it is necessary to understand
the relationship between stem cells, hematopoietic
progenitor cells, and TNF-a in the treatment of
myocardial injury.
There is evidence that while TNF-a is markedly
increased in the plasma of individuals with congestive
HF, the levels of CD34þ stem cells in peripheral blood,
endothelial progenitor cells (EPCs) in circulating
blood, and hematopoietic precursor cells in bone
marrow are decreased.52,53 Moreover, TNF-a can
directly inhibit infiltration of hematopoietic precursor
cells CD34þ induced by stem cell factor (SCF).54
Interestingly, the above injury function of TNF-a is
realized by the interaction with its receptor TNFR1;
however, when combined with TNFR2, the complex is
conducive to maintain the function of the stem cell. For
example, Chen et al55 found that cardiomyocytes
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face of the embryonic stem cells led to more migration
and differentiation of embryonic stem cells into car-
diomyocytes. Studies also found that mesenchymal
stem cells expressing TNFR2 could reduce inflamma-
tory reactions and improve cardiac function in in-
dividuals with MI.56 In addition, TNF-a may also
promote the secretion of GM-CSF to influence the
differentiation of stem cells.57 In conclusion, the ligand
types of TNF-a play an important role in the regulation
of stem cell function, and the synthesis and regulation
depend on the amount and proportion of TNFR1 and
TNFR2 expressed.
Conclusions
Since TNF-a was first described in 1975, many
studies about the correlation of TNF-a and MI had
been published. Through decades of effort, some
mechanisms of TNF-a in the progress of MI have been
identified, such as the polymorphisms in gene expres-
sion, inflammatory reaction, metabolic regulation, and
the change of the ion flow channel. Despite the un-
derstanding we have gained over the past several de-
cades, there are still many gaps in it: for example,
specific regulation of the polymorphism of coding
TNF-a gene promoter region to the expression of TNF-
a and its interaction with various environmental factors
to affect MI progress. In addition, when to use the
TNF-a antagonists in the treatment of HF and how
much the amount is the most suitable all remain to be
elucidated in the further experiments. Considering the
roles of TNF-a in MI and its subsequent progress,
further investigation on the mechanism of TNF-a will
promote better treatment of MI and its complications.
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